Watch CEO Linda Persson summarise the fourth quarter, with a primary focus on the clinical study that started in October. Just before the end of the year, we were able to report that the study is progressing as planned and that half of the twelve planned participants have completed the study protocol.
“For the first time, we have now been able to demonstrate that iron oxide-based nanoparticles have been identified in the lymph nodes of study participants using NanoEcho’s innovative diagnostic method, magnetomotive ultrasound. This confirms that our diagnostic system is functioning as intended in the study – a significant milestone for the company,”comments CEO Linda Persson.
The full report is available here!
